Fosun Pharma (600196.SH): A drug SRT-003-1 of its controlled subsidiary has been approved for clinical trials.

date
16/11/2026
Zhitong Finance APP news, Fosun Pharma (600196.SH) announced that recently, the company's controlled subsidiary Chengdu Xingrui Jingxuan Biotechnology Co., Ltd. (referred to as "Xingrui Jingxuan") received approval from the National Medical Products Administration for the clinical trial of [18F]F-SR031 injection (referred to as "SRT-003-1") for positron emission tomography (PET) imaging of fibroblast activation protein (FAP)-positive lesions in patients with solid tumors. Xingrui Jingxuan plans to conduct Phase I clinical research of the drug in China once conditions are met.